Stem-cell transplantation in chronic lympocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 3, 2007, Pages 513-527

  Gribben, John G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

chronic lymphocytic leukemia; donor lymphocyte infusions; graft versus host disease; graft versus leukemia; stem cell transplantation

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; PROTEIN KINASE ZAP 70; PROTEIN P53; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CYTOGENETICS; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEASIBILITY STUDY; GENE DELETION; GENE MUTATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LUNG CANCER; MELANOMA; MINIMAL RESIDUAL DISEASE; MORBIDITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASIA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; REDUCED INTENSITY CONDITIONING; REVIEW; RISK FACTOR; SKIN CANCER; SURVIVAL TIME; T CELL DEPLETION; TREATMENT FAILURE; WHOLE BODY RADIATION;

GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MIDDLE AGED; PATIENT SELECTION; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 34547919253     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.03.003     Document Type: Review

References (57)

1. Shanafelt T.D., Geyer S.M., and Kay N.E. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103 4 (2004) 1202-1210
2. Seiler T., Dohner H., and Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Seminars in Oncology 33 2 (2006) 186-194
3. Philip T., Armitage J.O., Spitzer G., et al. High-dose therapy and autologous marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. The New England Journal of Medicine 316 (1987) 1493-1498
4. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. Journal of Clinical Oncology 21 21 (2003) 3918-3927
5. Burnett A.K., Wheatley K., Goldstone A.H., et al. The value of allogeneic marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology 118 2 (2002) 385-400
6. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102 4 (2003) 1232-1240
7. Dombret H., Gabert J., Boiron J.M., et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 100 7 (2002) 2357-2366
8. Sebban C., Lepage E., Vernant J.P., et al. Allogeneic marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 12 12 (1994) 2580-2587
9. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine 335 2 (1996) 91-97
10. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine 343 26 (2000) 1910-1916
11. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 6 (1999) 1840-1847
12. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 6 (1999) 1848-1854
13. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. The New England Journal of Medicine 348 18 (2003) 1764-1775
14. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine 351 9 (2004) 893-901
15. Orchard J.A., Ibbotson R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 363 9403 (2004) 105-111
16. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21 1 (2007) 12-17
17. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 3 (2006) 885-891
18. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 23 18 (2005) 4079-4088
19. Hallek M. Chronic Lymphocytic Leukemia (CLL): First-Line Treatment. Hematology/The Education Program of the American Society of Hematology (2005) 285-291
20. Dreger P., Stilgenbauer S., Benner A., et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 103 7 (2004) 2850-2858
21. Rabinowe S.N., Soiffer R.J., Gribben J.G., et al. Autologous and allogeneic marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82 4 (1993) 1366-1376
22. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 106 (2005) 4389-4396
23. Khouri I.F., Keating M.J., Vriesendorp H.M., et al. Autologous and allogeneic marrow transplantation for chronic lymphocytic leukemia: preliminary results. Journal of Clinical Oncology 12 4 (1994) 748-758
24. Dreger P., von Neuhoff N., Kuse R., et al. Early stem cell transplantation for chronic lymphocytic leukemia: a chance for cure?. British Journal of Cancer 77 12 (1998) 2291-2297
25. Pavletic Z.S., Bierman P.J., Vose J.M., et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Annals of Oncology 9 9 (1998) 1023-1026
26. Milligan D.W., Fernandes S., Dasgupta R., et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105 1 (2005) 397-404
27. Jantunen E., Itala M., Siitonen T., et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukemia: the Finnish experience. Bone Marrow Transplantation 37 12 (2006) 1093-1098
28. Sutton L., Maloum K., Gonzalez H., et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia 12 11 (1998) 1699-1707
29. Itala M., Pelliniemi T.T., Rajamaki A., et al. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplantation 19 7 (1997) 647-651
30. Michallet M., Thiebaut A., Dreger P., et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukemias Working Party (CLWP). British Journal of Haematology 108 3 (2000) 595-601
31. Rawstron A.C., Kennedy B., Evans P.A., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98 1 (2001) 29-35
32. Provan D., Bartlett-Pandite L., Zwicky C., et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after marrow transplantation. Blood 88 6 (1996) 2228-2235
33. Schey S., Ahsan G., and Jones R. Dose intensification and molecular responses in patients with chronic lymphocytic leukemia: a phase II single centre study. Bone Marrow Transplantation 24 9 (1999) 989-993
34. Schultze J.L., Donovan J.W., and Gribben J.G. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. Journal of Molecular Medicine 77 2 (1999) 259-265
35. Zenz T., Ritgen M., Dreger P., et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 108 6 (2006) 2127-2130
36. Montillo M., Tedeschi A., Miqueleiz S., et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 24 15 (2006) 2337-2342
37. Jantunen E., Itala M., Siitonen T., et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1482 patients transplanted in 1990-2003. European Journal of Haematology 77 2 (2006) 114-119
38. Ritgen M., Lange A., Stilgenbauer S., et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 101 5 (2003) 2049-2053
39. Michallet M., Archimbaud E., Bandini G., et al. HLA-identical sibling marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for blood and marrow transplantation and the International marrow transplant registry. Annals of Internal Medicine 124 (1996) 311-315
40. Khouri I., and Champlin R. Allogenic marrow transplantation in chronic lymphocytic leukemia. Annals of Internal Medicine 125 9 (1996) 780-787
41. Pavletic Z.S., Arrowsmith E.R., Bierman P.J., et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplantation 25 7 (2000) 717-722
42. Doney K.C., Chauncey T., and Appelbaum F.R. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplantation 29 10 (2002) 817-823
43. Khouri I.F., Przepiorka D., van Besien K., et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. British Journal of Haematology 97 2 (1997) 466-473
44. Toze C.L., Galal A., Barnett M.J., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplantation 36 9 (2005) 825-830
45. Moreno C., Villamor N., Colomer D., et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 23 15 (2005) 3433-3438
46. Horowitz M., Montserrat E., Sobocinski K., et al. Haemopoietic stem cell transplantation for chronic lymphocytic leukemia. Blood 96 supplement 1 (2000) 522a
47. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. Journal of Clinical Oncology 16 (1998) 2817-2824
48. Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of Clinical Oncology 21 14 (2003) 2747-2753
49. Dreger P., Brand R., Hansz J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17 5 (2003) 841-848
50. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 23 (2005) 3819-3829
51. Khouri I.F. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology/The Education Program of the American Society of Hematology (2006) 390-397
52. Brown J.R., Kim H.T., Li S., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biology of Blood and Marrow Transplantation 12 10 (2006) 1056-1064
53. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 13 (2001) 3595-3599
54. Delgado J., Thomson K., Russell N., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 107 4 (2006) 1724-1730
55. Dreger P., Brand R., Milligan D., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19 6 (2005) 1029-1033
56. Caballero D., Garcia-Marco J.A., Martino R., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clinical Cancer Research 11 21 (2005) 7757-7763
57. Khouri I.F., Saliba R.M., and Keating M.J. ZAP-70 status may not predict outcome after non-myeloablative allogeneic transplantation (NMT) in patients with chronic lymphocytic leukemia (CLL) who failed conventional chemotherapy. Blood 106 supplement 1 (2005) 577a